🧬 Phacilitate presents what’s ahead at Advanced Therapies Europe 2025!

Becky Johnson-Kent, global event director of #Phacilitate; i Ingerid Sorgaard, content director of Phacilitate

Advanced Therapies Europe 2025: A New Era for Cell and Gene Therapy Conferences The upcoming Advanced Therapies Europe 2025 conference in Barcelona promises an innovative format. Capped at 500 attendees, it focuses on fostering connections and driving breakthroughs in cell and gene therapies.

Advanced Therapies Europe 2025: A New Era for Cell and Gene Therapy Conferences #Spain #Barcelona #Advanced_Therapies #Phacilitate

Innovative Format Unveiled for Advanced Therapies Europe 2025 Advanced Therapies Europe 2025 will debut in Barcelona with a revamped format, focusing on high-value interactions for 500 exclusive attendees.

Innovative Format Unveiled for Advanced Therapies Europe 2025 #Spain #Barcelona #Advanced_Therapies #Phacilitate

Advanced Therapies Europe 2025 Sets the Stage for Innovation in Barcelona with Exclusive Format Join the advanced therapies community in Barcelona from September 2-4, 2025, for exclusive networking and insights into the future of cell and gene therapies.

Advanced Therapies Europe 2025 Sets the Stage for Innovation in Barcelona with Exclusive Format #Spain #Barcelona #Advanced_Therapies #Phacilitate

Discover Advanced Therapies Europe 2025: A New Impactful Event Format in Barcelona Advanced Therapies Europe 2025 is set to make its debut in Barcelona, offering a unique experience with limited attendance for deeper connections.

Discover Advanced Therapies Europe 2025: A New Impactful Event Format in Barcelona #Spain #Barcelona #Advanced_Therapies #Phacilitate

Listening to #sanofi scientist explain that #iniparib isn't really a #PARP inihibitor. They should've called it notaparib. #Phacilitate

#Phacilitate Oncology Leaders' Forum. Bueller .... Bueller ....

Reed Tuckson from #UnitedHealth gives barnburner on unsustainability of our healthcare system at #Phacilitate oncology leaders' forum

Speaking at the #Phacilitate Oncology Leaders' Forum this afternoon on why #PI3K pathway drugs have dissapointed us thus far.